Overall, AKT inhibitors have shown a lack of correlation between PI3K/AKT pathway alterations and efficacy of AKT inhibitors from HR+ BC patients with limited data available on HER2+ and a positive trend in TNBC patients.
← all excerpts
Genomic Predictive Biomarkers in Breast Cancer: The <i>Haves</i> and <i>Have Nots</i>.
1
—
—